12:00 AM
May 21, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Selumetinib: Phase I started

Cancer Research UK began a 2-part, U.K Phase I trial to evaluate the combination of once-daily oral Caprelsa vandetanib and twice-daily oral selumetinib in up to 48 patients. The first part will evaluate escalating doses of 25, 50 and 75 mg selumetinib in combination with Caprelsa in up to 18...

Read the full 247 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >